Grants for Independent School Districts

The "Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research" grant aims to fund exploratory research projects that focus on the development of innovative technologies for analyzing molecular or cellular aspects of cancer, with the goal of improving cancer biology research, early detection, diagnosis, treatment, control, epidemiology, and addressing health disparities related to cancer.

The "Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research" grant aims to fund exploratory research projects that focus on improving the quality of cancer samples through the development and validation of innovative technologies, which will help in preserving sample integrity, establishing quality control, and reducing variations in sample quality, ultimately enhancing cancer research, diagnosis, and treatment.

This funding opportunity provides financial support to organizations that enhance the quality of life for residents within the Boyertown Area School District through health, social, recreational, and safety initiatives.

The "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research" grant aims to encourage existing NCI P30 centers to enhance their current research by integrating new technologies from the NCI Innovative Molecular Analysis Technologies program, with the goal of advancing cancer research and promoting scientific discovery.

The "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research" grant aims to encourage current NCI R01 research projects to incorporate new technologies from the NCI Innovative Molecular Analysis Technologies program, with the goal of enhancing their original research and speeding up scientific discoveries in cancer research.

The "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research" grant aims to encourage existing NCI P50 specialized centers to enhance their current cancer research by integrating new technologies or methods developed by the NCI Innovative Molecular Analysis Technologies program.

The "Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research" grant aims to fund the development of innovative technologies that enhance the quality of biological samples used in cancer research, by addressing issues related to sample degradation during collection, processing, and storage, and by establishing quality control measures.

The "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research" grant aims to encourage current NCI U01 research projects to incorporate new technologies from the NCI Innovative Molecular Analysis Technologies program, in order to enhance their original research and speed up scientific discoveries in cancer research.

This grant provides funding to non-profit organizations, schools, and government entities that serve the residents of Henry County in areas such as health, education, social services, cultural affairs, and civic affairs.

This funding opportunity supports coalitions of organizations in the Kansas City region working together to create lasting solutions that improve economic mobility for local residents.

TheNational Institute of Allergy and Infectious Diseases (NIAID),intendstopublish a Notice of Funding Opportunity (NOFO) tosolicit applications for a Center of Excellence (CoE) for Systems Modeling of Infection and Immunity across Biological Scales that will: Develop and conduct innovative computational multi-scale modeling research for NIAID priority biomedical questions, including HIV/AIDS; Coordinate the NIAID and broader modeling community that conducts research on infectious- and immune-mediated diseases, through model and data sharing, opportunity funds, educational activities, and community-organizing activities; Conduct innovative research and coordination activities to improve data and model sharing in the NIAID and broader modeling community; Foster a diverse community of new and existing investigators dedicated to Infectious and Immune-mediated Disease (IID) multi-scale modelingand collaboration between experimental and computational scientists; Serve as point of contact to NIAID for the modeling community and pivot research activities to address acutely emerging NIAID needs, such as outbreaks, epidemics, or pandemics; Establish community development and educational opportunities in IID multi-scale modeling for students, post-doctoral fellows, and new/early-stage investigators; Enable new approaches for multi-scale model sharing and reproducibility aligned with theFAIR (Findable, Accessible, Interoperable, and Reusable) principles and theNIAID Data Ecosystem Portal. This Notice isbeing provided toallow potential applicants sufficient timetodevelop meaningful collaborations andprojects. Potentialapplicantsareencouraged tousethistimetodevelop leadership teams to cover the full range of expertise and experience to develop the coordinating cores and research projects that will represent and enable strong scientific and operational connections between the CoE and the larger IID modeling community. This NOFO will utilize theU54 activity code.Details for a pre-application webinar will be provided in the published NOFO.

The purpose of this Notice is to announce the intention of National Institutes of Neurological Disorders and Stroke (NINDS) to reissue RFA-NS-21-021 to solicit applications for research pursuing translational activities and small clinical studies to advance the development of low risk therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in Spring 2024 with an expected application due date in Summer 2024. This NOFO will utilize the R61/R33 activity code. Details of the planned NOFO are provided below.

This funding opportunity provides financial support for non-profit organizations, community groups, and individuals working on charitable projects that improve the quality of life in Smith County.

This funding opportunity provides up to $1,000 to Seattle schools, PTAs, and community groups to encourage safe walking and biking to school through various programs and events.

This funding opportunity supports collaborative efforts among tax-exempt organizations and local governments in El Paso and Teller Counties, Colorado, to address community health challenges through innovative programs and evidence-based practices.

This Notice of Intent to Publish is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects for the following Notice of Funding Opportunity (NOFO), which is expected to be published in January 2024, with an anticipatedapplication receipt date in May 2024. The Brain Research through Advancing Innovative Neurotechnologies(BRAIN) Initiative intends to promote a new initiative by publishing a NOFO to solicit applications that would support development and preclinical testing, beginning withproof of concept,of next-generation recording and/or modulation devices for human use to further our understanding of the human central nervous system and treat nervous system disorders. This NOFO will utilize the R18 activity code. Details of the planned NOFO are provided below.

The U.S. Food and Drug Administration (FDA) seeks applications to develop, implement, and evaluate a human abuse potential (HAP) study of botanical Kratom. FDA has previously warned consumers about the use of Kratom (Mitragyna speciosa), a plant indigenous to Southeast Asia. Kratom alkaloids have demonstrated both affinity and activity at receptor sites known to be associated with abuse, such as mu opioid receptors. Although Kratom use is prevalent, to date, clinical evaluations of its abuse potential have been limited. The proposed HAP study should be performed in accordance with the guidance for industry, "Assessment of Abuse Potential of Drugs," including (but not limited to) the selection of an appropriate comparator(s) and outcome measures, statistical analyses etc. Interested parties, will also complete the submission of an Investigational New Drug (IND) application and obtain Institutional Review Board (IRB) clearance.

This grant provides funding and support for organizations serving low-income youth to create custom-designed multi-sport courts that promote physical activity and community engagement.

This funding opportunity provides additional financial support to researchers with existing NIH grants to expand their projects and address new scientific challenges or opportunities.

Modified release (MR) oral drug products are considered to have a high risk for alcohol dose dumping (ADD) because they contain large quantities of drug(s), designed to release over a prolonged period of time. Accidental exposure of these products to alcohol can result in the relatively rapid release of large quantities of drug with severe side effects, including death. To mitigate this risk, the FDA recommends conducting an in vitro alcohol dose dumping assessment in 0%, 5%, 20%, and 40% alcoholic dissolution media for all prospective generic versions of MR oral drug products. To date, ADD assessments have not been harmonized globally. For instance, the U.S. FDA recommends testing up to 40% alcoholic media while the European Medicines Agency recommends testing up to 20% alcoholic media. This type of difference can present a challenge for formulators designing products for multiple markets, as historical data has shown release from MR oral products do not always follow a linear response (either increasing or decreasing) to increasing alcohol concentrations. In addition, interpretation of an ADD assessment may be limited by the inability of the test to predict in vivo behavior. The purpose of this research is to develop tools that 1) facilitate the development of MR generic drug products that have a low potential for ADD, 2) support regulatory decision making during the assessment of such products, and 3) provide evidence that enables FDA to develop more specific recommendations for efficiently demonstrating a low or comparative potential of alcohol dose dumping for MR oral drug products containing high risk drugs.